about
Toxicity of amphetamines: an updateInfant autonomic functioning and neonatal abstinence syndromeSubcortical and cortical structural central nervous system changes and attention processing deficits in preschool-aged children with prenatal methamphetamine and tobacco exposure.Placental 11-beta hydroxysteroid dehydrogenase methylation is associated with newborn growth and a measure of neurobehavioral outcome.Structural, metabolic, and functional brain abnormalities as a result of prenatal exposure to drugs of abuse: evidence from neuroimaging.Maternal depression and anxiety are associated with altered gene expression in the human placenta without modification by antidepressant use: implications for fetal programmingPregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomesPrenatal methamphetamine exposure and inhibitory control among young school-age childrenSelective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark.A steep learning curve: decoding epigenetic influence on behavior and mental healthCortisol reactivity in two-year-old children prenatally exposed to methamphetaminePrenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and serotonin transporter promoter genotype (SLC6A4) influence executive functions at 6 years of age.Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screenExamining the relationships between prenatal methamphetamine exposure, early adversity, and child neurobehavioral disinhibitionAgainst professional advice: treatment attrition among pregnant methamphetamine users.Cross-national comparison of prenatal methamphetamine exposure on infant and early child physical growth: a natural experiment.Prenatal methamphetamine exposure and neurodevelopmental outcomes in children from 1 to 3 years.The Epigenetic Link between Prenatal Adverse Environments and Neurodevelopmental Disorders.Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus?Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a "social teratogen" or moderator of developmental risk?Monoamine oxidases in development.Effects of prenatal methamphetamine exposure: a review of cognitive and neuroimaging studies.Long-term health consequences of early-life exposure to substance abuse: an epigenetic perspective.Neonatal Abstinence Syndrome: Update on Diagnostic and Therapeutic Strategies.Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence.Placental and fetal effects of antenatal exposure to antidepressants or untreated maternal depression.Adenosine receptor antagonists including caffeine alter fetal brain development in mice.Street drug use during pregnancy: potential programming effects on preschool wheeze.Prenatal methamphetamine exposure is associated with reduced subcortical volumes in neonates.Coordinated expression of dopamine transporter and vesicular monoamine transporter in the primate striatum during development.
P2860
Q22252794-0B4BDC94-6F5F-4397-B234-B5CDFFD3B905Q33872350-4DF99A6D-1A2E-42FC-8EEB-873FF72AE880Q33878485-5629B937-3C58-4BBD-A6B4-01713C04E031Q34203026-39E58E7A-60E0-4099-B6F8-8BC1CA43D7F0Q34336685-F8C57BD3-3C09-4A13-8C81-F9A8589090C0Q35161157-56B598FF-88EC-4235-8F15-C627EE4C5B5EQ35783426-DE90882F-1B5D-4735-9601-E68F92CB1360Q36084014-9F89803A-5AC6-44F2-95A4-DB6FA5D05B87Q36209588-8BF711E8-7AE2-4DFB-B90A-A8626798AFEFQ36379843-A8B935FA-866E-4A9E-90DF-755F4182BD9DQ36698912-43CF28F8-E74B-4038-97CE-929A7FEB114AQ37226375-80576793-539C-47CB-A92B-3EF628CF51A3Q37235692-1AA96A3F-79A1-45B9-BE4B-1A750C5214CBQ37347114-25FF258C-9F33-46B7-A56D-053D77A4C4BCQ37355281-4AF378B0-EE16-40C8-B810-818F87C6A4F1Q37627099-4996473D-B263-4BDD-9571-ABA7507D1851Q37719523-7E11BF17-FB76-4A8E-BDBE-586FB01BB9C7Q37724137-281E9655-200F-4BEE-BA7B-23BA858A3B62Q37922189-FF9DD306-F61C-4C52-B877-4DFB46E1F8D0Q38021727-A46B20B9-E152-4BC4-953A-D3B0D27B0B94Q38025300-2A7E27CE-0D92-45D2-889D-99EDB4C321C1Q38174009-4E1F9C66-6F66-4AC9-882B-4C0A0DED5338Q38226003-EC3746B6-7AED-4056-B900-78A515068543Q38682392-4146FE09-A8FF-45FA-A73E-1E436C1501C5Q38823790-FF078DAA-1B08-417F-9A14-DFC9A8A4DE67Q38845135-DD276B7F-5FCC-4E0B-8929-909874F536FDQ46127416-E9A1BE22-31D7-4441-B212-DA4FF01E5101Q46278927-6F096E59-F02D-40ED-B48F-7A71ED4EDC25Q46798876-0D07028A-8F7D-4BF7-A953-0219D206A64EQ48136215-538B3AAF-1378-4C53-ACE0-EB36E9EEFDFA
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Fetal effects of psychoactive drugs
@ast
Fetal effects of psychoactive drugs
@en
type
label
Fetal effects of psychoactive drugs
@ast
Fetal effects of psychoactive drugs
@en
prefLabel
Fetal effects of psychoactive drugs
@ast
Fetal effects of psychoactive drugs
@en
P2093
P2860
P1476
Fetal effects of psychoactive drugs
@en
P2093
Amy L Salisbury
James F Padbury
Kathryn L Ponder
P2860
P304
P356
10.1016/J.CLP.2009.06.002
P50
P577
2009-09-01T00:00:00Z